Zou Youran, Zhang Yaxia, Church James, Liu Xiuli
Departments of Department of Pathology.
Department of Colorectal Surgery, Cleveland Clinic, Cleveland, OH.
Appl Immunohistochem Mol Morphol. 2018 Oct;26(9):648-653. doi: 10.1097/PAI.0000000000000487.
β-catenin immunohistochemical stain can be useful in the diagnosis of many tumors including desmoid-type fibromatosis (DTF). Lymphoid enhancer-factor 1 (LEF1), a recently emerged marker, is part of the Wnt pathway with β-catenin but has not been studied in DTF. We performed LEF1 and β-catenin immunohistochemistry in DTF (n=26), superficial fibromatosis (n=19), sclerosing mesenteritis (n=12), gastrointestinal stromal tumor (n=17), and cutaneous scar (n=14) using tissue microarray and whole sections. The staining intensity was scored as strong (visible at ×2 objective, value of 3), moderate (visible at ×4, value of 2), weak (visible at ×10, value of 1), and negative (not visible at ×10, value of 0). The percentage of positive nuclei was recorded in 10% increment. Histologic scores were generated by multiplying numerical value of intensity and percentage of positive nuclei. A score of at least 10 was defined as positive. Eighteen of the 25 DTF were positive for LEF1 while 12 of 25 were positive for β-catenin (1 excluded due to loss of tissue). Gastrointestinal stromal tumor cases were negative for both markers. All superficial fibromatoses were negative except 2 cases with weak positivity for LEF1 but not β-catenin. Only 2 case of sclerosing mesenteritis were weakly positive for LEF1 but negative for β-catenin. Ten of 14 scars were positive for LEF1 but only 1 of them was weakly positive for β-catenin. In conclusion, this study demonstrated that LEF1 may be a useful marker in the differential diagnosis of DTF in certain contexts. However, caution should be exercised since LEF1 positivity can also be seen in scars.
β-连环蛋白免疫组化染色在包括硬纤维瘤型纤维瘤病(DTF)在内的许多肿瘤诊断中可能有用。淋巴增强因子1(LEF1)是一种最近出现的标志物,它是与β-连环蛋白共同参与Wnt信号通路的一部分,但尚未在DTF中进行研究。我们使用组织芯片和全切片对DTF(n = 26)、浅表性纤维瘤病(n = 19)、硬化性肠系膜膜炎(n = 12)、胃肠道间质瘤(n = 17)和皮肤瘢痕(n = 14)进行了LEF1和β-连环蛋白免疫组化检测。染色强度分为强(在×2物镜下可见,评分为3)、中(在×4物镜下可见,评分为2)、弱(在×10物镜下可见,评分为1)和阴性(在×10物镜下不可见,评分为0)。阳性细胞核的百分比以10%的增量记录。组织学评分通过将强度数值与阳性细胞核百分比相乘得出。至少10分被定义为阳性。25例DTF中有18例LEF1阳性,25例中有12例β-连环蛋白阳性(1例因组织丢失被排除)。胃肠道间质瘤病例两种标志物均为阴性。除2例LEF1弱阳性但β-连环蛋白阴性的浅表性纤维瘤病外,所有浅表性纤维瘤病均为阴性。硬化性肠系膜膜炎仅2例LEF1弱阳性但β-连环蛋白阴性。14例瘢痕中有10例LEF1阳性,但其中只有1例β-连环蛋白弱阳性。总之,本研究表明,在某些情况下,LEF1可能是DTF鉴别诊断中的一个有用标志物。然而,由于在瘢痕中也可见到LEF1阳性,因此应谨慎使用。